Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Feb;23(2):286-289.
doi: 10.1002/ejhf.2104. Epub 2021 Jan 26.

Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs

Claudio Rapezzi  1   2 , Alberto Aimo  3   4 , Michele Emdin  3   4
Affiliations
Free article
Editorial

Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs

Claudio Rapezzi et al. Eur J Heart Fail. 2021 Feb.
Free article
No abstract available

PubMed Disclaimer

Comment on

References

    1. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007-1016.
    1. Nawarskas JJ, Shephard EA. Tafamidis: a novel treatment for transthyretin amyloid cardiomyopathy. Cardiol Rev 2020;28:156-160.
    1. Lockwood PA, Le VH, O'Gorman MT, Patterson TA, Sultan MB, Tankisheva E, Wang Q, Riley S. The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4 × 20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev 2020;9:849-854.
    1. Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail 2021;23:277-285.
    1. Bezerra F, Saraiva MJ, Almeida MR. Modulation of the mechanisms driving transthyretin amyloidosis. Front Mol Neurosci 2020;13:592644.

LinkOut - more resources